Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Published:2019-07-29 Issue:20 Volume:125 Page:3514-3525
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Roberts Ryan D.¹^ORCID,Lizardo Michael M.²,Reed Damon R.³^ORCID,Hingorani Pooja⁴,Glover Jason⁵,Allen‐Rhoades Wendy⁶⁷,Fan Timothy⁸,Khanna Chand⁹¹⁰,Sweet‐Cordero E. Alejandro¹¹,Cash Thomas¹²,Bishop Michael W.¹³^ORCID,Hegde Meenakshi¹⁴,Sertil Aparna R.¹⁵,Koelsche Christian¹⁶,Mirabello Lisa¹⁷,Malkin David¹⁸¹⁹,Sorensen Poul H.²⁰²¹,Meltzer Paul S.²²,Janeway Katherine A.²³,Gorlick Richard²⁴,Crompton Brian D.²⁵

Affiliation:

1. Center for Childhood Cancer Nationwide Children's Hospital, The Ohio State University James Comprehensive Cancer Center Columbus Ohio

2. Department of Molecular Oncology BC Cancer, Provincial Health Services Authority Vancouver British Columbia Canada

3. Sarcoma Department, Chemical Biology and Molecular Medicine Program and Adolescent and Young Adult Oncology Program Moffitt Cancer Center Tampa Florida

4. Center for Cancer and Blood Disorders Phoenix Children's Hospital Phoenix Arizona

5. Children's Cancer and Blood Disorders Program Randall Children's Hospital Portland Oregon

6. Department of Pediatrics, Section of Hematology‐Oncology Baylor College of Medicine Houston Texas

7. Texas Children's Hospital Cancer and Hematology Centers Houston Texas

8. Department of Veterinary Clinical Medicine University of Illinois Urbana‐Champaign Illinois

9. Ethos Vet Health Woburn Massachusetts

10. Ethos Discovery (501c3) Washington, DC

11. Division of Hematology and Oncology, Department of Pediatrics University of California San Francisco San Francisco California

12. Department of Pediatrics Emory University, Children's Healthcare of Atlanta Atlanta Georgia

13. Department of Oncology St. Jude Children's Research Hospital Memphis Tennessee

14. Center for Cell and Gene Therapy Texas Children's Hospital, Baylor College of Medicine Houston Texas

15. Department of Basic Medical Sciences, College of Medicine Phoenix University of Arizona Phoenix Arizona

16. Department of General Pathology, Institute of Pathology Ruprecht‐Karls‐University Heidelberg Germany

17. Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health Bethesda Maryland

18. Hospital for Sick Children Toronto Ontario Canada

19. Department of Pediatrics Division of Hematology/Oncology University of Toronto Toronto Ontario Canada

20. Department of Molecular Oncology BC Cancer, Provincial Health Services Authority, Vancouver British Columbia Canada

21. Department of Pathology and Laboratory Medicine University of British Columbia, Vancouver British Columbia Canada

22. Genetics Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland

23. Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Boston Massachusetts

24. Division of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas

25. Dana‐Farber Cancer Institute, Boston, and Broad Institute of Harvard and MIT Cambridge Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32351

Reference92 articles.

1. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

2. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

3. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

4. Children's Oncology Group's 2013 blueprint for research: Bone tumors

5. Maximum benefit of chemotherapy for osteosarcoma achieved—what are the next steps?

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Clinical, pathologic and molecular findings in 2 Rottweiler littermates with appendicular osteosarcoma;Veterinary Oncology;2024-08-06

3. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

4. A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics;2024-06-20

5. Comparative responses to demethylating therapy in animal models of osteosarcoma;2024-06-11